Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating ...
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology ...
A potential first-in-class therapy for migraine prevention has shown promise in a phase 2a proof-of-concept study, with a single infusion reducing migraine frequency over 4 weeks. The drug Lu AG09222 ...
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab ...
Internist Vincent Martin, MD, said every primary care clinician should know about calcitonin gene-related peptide (CGRP) monoclonal antibodies for preventing migraines. These newer drugs are changing ...
TEV-48125, a monoclonal anti-calcitonin-gene related peptide (CGRP) antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from ...
Please provide your email address to receive an email when new articles are posted on . A majority of patients had initial or sustained significant symptom improvement, with few adverse effects. Most ...
The past several years have seen more advancements in migraine-specific treatments than in the past three decades. Let that sink in. Since 2018, several new therapies have emerged to both treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results